Buzz: Baxter is considering selling its vaccine unit

Baxter announced Thursday morning it will split into two companies, separating its $6 billion biopharma operation from its $9 billion medical device and diagnostics business. The company is also looking into selling its vaccine business, Reuters reported Wednesday. The process is at an early stage, with Baxter having recently tapped Goldman Sachs to advise and begun contacting potential buyers, including private equity firms. Sales of vaccines against meningitis C and tick-borne encephalitis helped the business bring in $300 million last year. The unit is profitable, but Baxter reportedly considers it noncore. Novartis ($NVS) is also thinking of selling its vaccine unit. Article | More from FierceBiotech

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.